louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02593617: The Effect of Energy Drink Consumption on Alcohol-Substance Use and It's Relationship With Impulsivity In University Students
Official title: The Effect of Energy Drink Consumption on Alcohol-Substance Use and It's Relationship With Impulsivity In University Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Energy Drinks
Alcohol Drinking
Substance Use
University Students
Keywords: Energy Drinks
Alcohol Drinking
Substance Use
Lead sponsor: Mustafakemalpasa State Hospital
Sponsor class: OTHER
First posted: 2015-11-01
Enrollment: 2623
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The objective of this study is to investigate the prevalence of energy drink, alcohol and substance use among university students; to explore whether there is a relationship between energy drink consumption and alcohol-substance use in university students or not and to evaluate effect of impulsiveness and sensation seeking on this relationship.


Eligibility criteria: Inclusion Criteria:

* To be university student
* To be ≥ 18 years old

Exclusion Criteria:

* Not willing to participate the study

Primary outcomes:
measure: Measurement of the prevalence of energy drink consumption among university students by using energy drink consumption questionnaire
timeFrame: One hour
measure: Measurement of the prevalence of alcohol consumption among university students by using addiction profile index
timeFrame: One hour
measure: Measurement of the prevalence of substance use among university students by using addiction profile index
timeFrame: One hour
measure: Assessment of sensation seeking among university students by using Zuckerman Sensation Seeking Scale
timeFrame: One hour
measure: Assessment of impulsivity among university students by using Barratt Impulsiveness Scale
timeFrame: One hour
Secondary outcomes:
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Mustafakemalpasa State Hospital
Study officials:
References:
citation: Arria AM, Caldeira KM, Kasperski SJ, Vincent KB, Griffiths RR, O'Grady KE. Energy drink consumption and increased risk for alcohol dependence. Alcohol Clin Exp Res. 2011 Feb;35(2):365-75. doi: 10.1111/j.1530-0277.2010.01352.x. Epub 2010 Nov 12.
citation: Brache K, Stockwell T. Drinking patterns and risk behaviors associated with combined alcohol and energy drink consumption in college drinkers. Addict Behav. 2011 Dec;36(12):1133-40. doi: 10.1016/j.addbeh.2011.07.003. Epub 2011 Jul 23.
citation: Marczinski CA. Alcohol mixed with energy drinks: consumption patterns and motivations for use in U.S. college students. Int J Environ Res Public Health. 2011 Aug;8(8):3232-45. doi: 10.3390/ijerph8083232. Epub 2011 Aug 5.
citation: Velazquez CE, Poulos NS, Latimer LA, Pasch KE. Associations between energy drink consumption and alcohol use behaviors among college students. Drug Alcohol Depend. 2012 Jun 1;123(1-3):167-72. doi: 10.1016/j.drugalcdep.2011.11.006. Epub 2011 Dec 3.
Clinical trial NCT06764017: CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Official title: A Single-arm, Multicenter, Prospective Clinical Study of CHiR (chidamide, Zanubrutinib, and Lenalidomide) for Newly Diagnosed MYC- and BCL2-positive Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Diffuse Large B-Cell Lymphoma
Keywords: diffuse large B-cell lymphoma
MYC- and BCL2-positive
chidamide
zanubrutinib
lenalidomide
elderly patients
Lead sponsor: First Affiliated Hospital of Ningbo University
Sponsor class: NETWORK
First posted: 2025-01-08
Enrollment: 30
Sex: ALL
Minimum age (years): 70
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.


Eligibility criteria: Inclusion Criteria：

1. Age ≥ 70 years;
2. ECOG score of 0-3;
3. Rated as unfit or frail on the simplified geriatric assessment (sGA);
4. Histologically confirmed CD20-positive diffuse large B-cell lymphoma (diagnostic criteria according to WHO 2016), excluding transformed type 2 DLBCL;
5. Immunohistochemically confirmed positive expression of MYC and BCL2 (MYC ≥ 40%, BCL2 ≥ 50% by immunohistochemistry);
6. Previously untreated patients;
7. Cardiac, hepatic, and renal function: creatinine \< 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase)/AST (aspartate aminotransferase) \< 2.5 ULN; total bilirubin \< 2 ULN;
8. At least one measurable lesion;
9. Unable to tolerate standard CHOP regimen chemotherapy or unwilling to receive chemotherapy;
10. Adequate understanding and voluntary signing of the informed consent form. Exclusion Criteria：

1.Patients with central nervous system involvement at the time of onset; 2.Known human immunodeficiency virus (HIV) infection; 3.Pregnant or lactating women; 4.Other tumors requiring treatment; 5.Uncontrollable active infection; 6.Active hepatitis with HBV-DNA copy number not controlled within 2\*1000/mL despite antiviral treatment; 7.Inability to understand, comply with the study protocol, or sign the informed consent form.

Primary outcomes:
measure: the complete remission rate (CRR)
timeFrame: Each cycle consists of 21 days, with a total of 8 cycles.
Secondary outcomes:
Other outcomes:
Locations:
city: Ningbo
country: China
facility: The First Affiliated Hospital of Ningbo University
state: Zhejiang
Study officials:
References:
Clinical trial NCT00219817: Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cancer Cachexia
Keywords: Anorexia
Cachexia
Lead sponsor: Helsinn Therapeutics (U.S.), Inc
Sponsor class: INDUSTRY
First posted: 2005-09-22
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.


Eligibility criteria: Inclusion Criteria:

* Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer.
* Involuntary loss of body weight of ≥ 5 % within the past 6 months

Exclusion Criteria:

* Presently hospitalized or in a nursing care facility.
* Inability to increase food intake from secondary causes.
* Liver disease
* If female-pregnant, breast-feeding or of childbearing potential.

Primary outcomes:
measure: Body Weight
measure: Lean Body Mass
measure: Functional Performance
Secondary outcomes:
Other outcomes:
Locations:
city: Greenbrae
country: United States
facility: California Cancer Care Center
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Galveston
country: United States
facility: University of Texas Medical Branch at Galveston
state: Texas
city: Houston
country: United States
facility: Michael E. DeBakey Veterans Affairs Medical Center
state: Texas
city: Burlington
country: United States
facility: Fletcher Allen Health Care
state: Vermont
city: Abingdon
country: United States
facility: Cancer Outreach Associates
state: Virginia
Study officials:
affiliation: Sapphire Therapeutics
name: William Polvino, MD
role: STUDY_DIRECTOR
References:
citation: Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16.
Clinical trial NCT02778217: Blastocyst Culture in a Time-lapse Incubator
Official title: The Blastocyst Development and Clinical Outcome in Single Step Medium With or Without Renewal on Day 3 in a Time-lapse Incubator
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sub-optimal Culture Conditions
Lead sponsor: Dar AlMaraa Center
Sponsor class: OTHER
First posted: 2016-05-19
Enrollment: 200
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Culture media used to support development of zygotes to the blastocyst stage is based on two basic philosophies: a single step medium "let-the-embryo-choose" or a sequential medium "back-to-nature".

For single step media, there are two types of protocol can be used for the culture of human preimplantation embryos:

1. Interrupted single medium culture, in which the medium is renewed on the Day 3 of embryo culture
2. Uninterrupted single embryo culture, in which the same single medium is used throughout the 5-6 days of culture with no replenishment or replacement on Day 3.

Investigators aim to compare the blastocyst development and clinical outcome between the two types of protocols of a single medium (with or without renewal on Day 3)


Eligibility criteria: Inclusion Criteria:

* female partners were under the age of 39 years
* Intracytoplasmic sperm injection (ICSI) was performed using fresh ejaculates

Exclusion Criteria:

* Day 3 embryo transfer cycles

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 4 weeks post embryo transfer
Secondary outcomes:
measure: Implantation rate
timeFrame: 4-6 weeks post embryo transfer
measure: Blastocyst formation rate
timeFrame: 5-6 days post intracytoplasmic sperm injection
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Sunrise fertility center
Study officials:
affiliation: Dar Almaraa fertility and gynacology center
name: Yasmin Magdi, M.Sc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Costa-Borges N, Belles M, Meseguer M, Galliano D, Ballesteros A, Calderon G. Blastocyst development in single medium with or without renewal on day 3: a prospective cohort study on sibling donor oocytes in a time-lapse incubator. Fertil Steril. 2016 Mar;105(3):707-713. doi: 10.1016/j.fertnstert.2015.11.038. Epub 2015 Dec 12.
Clinical trial NCT05232617: The Effects of Online Rheumatological Rehabilitation Education in Intern Physiotherapy Students
Official title: The Effects of Online Rheumatological Rehabilitation Education on Readiness, Clinical Decision Making and Perceived Self-efficacy in Intern Physiotherapy Students
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Learning Problem
Keywords: Learning management
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2022-02-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Intern physiotherapy students taking the Rheumatology Internship course at Istanbul University Cerrahpaşa Faculty of Health Sciences, Physiotherapy and Rehabilitation will be included in the study. In the 2020-2021 academic year, 60 intern physiotherapy students who took the Rheumatology Internship course will be included. Consent will be obtained from all participants with a voluntary information form on google forms.

Brief summary: The aim of the study is to investigate the effect of online rheumatological rehabilitation training on readiness, clinical decision making and perceived self-efficacy in intern physiotherapy students. In the study, online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. In the study, readiness, clinical decision making and perceived self-efficacy levels will be evaluated in intern physiotherapy students before and after online rheumatological rehabilitation training.


Eligibility criteria: Inclusion Criteria:

* To be taking Rheumatological Rehabilitation internship course

Exclusion Criteria:

* To have taken the Rheumatological Rehabilitation Internship course before, but failed to complete it successfully
* Lack of internet access

Primary outcomes:
measure: Readiness Scale for Mobile Learning
timeFrame: Change from baseline to 4 weeks
Secondary outcomes:
measure: Melbourne Decision-Making Scale I-II
timeFrame: Change from baseline to 4 weeks
measure: General Self-Efficacy Scale
timeFrame: Change from baseline to 4 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul University-Cerrahpasa
state: Buyukcekmece
Study officials:
References:
Clinical trial NCT04262817: The Interaction of Flavor With Nicotine Form in Adult Smokers
Official title: The Interaction of Flavor With Nicotine Form in Adult Smokers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Nicotine Dependence
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2020-02-10
Enrollment: 20
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study seeks to elucidate the impact of e-cigarette flavor on subjective effects and nicotine exposure from e-cigarettes containing different forms of nicotine.


Eligibility criteria: Inclusion Criteria:

* At least 21 years old, able to read and write, use of combustible

Exclusion Criteria:

-

Primary outcomes:
measure: Changes in Liking of E-cigarette Overall
timeFrame: up to 3 weeks
measure: Changes in Liking of E-cigarette Flavor
timeFrame: up to 3 weeks
Secondary outcomes:
measure: gLMS: Sweetness
timeFrame: up to 3 weeks
measure: gLMS: Coolness
timeFrame: up to 3 weeks
measure: gLMS: Irritation
timeFrame: up to 3 weeks
measure: Number of Puffs
timeFrame: up to 3 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pierce Laboratory
state: Connecticut
Study officials:
References:
Clinical trial NCT00969917: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Official title: A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Dedifferentiated Liposarcoma
Lead sponsor: Infinity Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2009-09-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age at the time of signing informed consent.
* Histologic diagnosis of dedifferentiated liposarcoma.
* Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading.
* At least one prior chemotherapy regimen for dedifferentiated liposarcoma.
* No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of non-chemotherapy regimens is permitted.
* Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion.
* Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
* Life expectancy ≥6 months.

Exclusion Criteria:

* Prior treatment with any heat shock protein 90 (Hsp90) inhibitor.
* Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease
* Patients with prior hepatic resections or hepatic-directed therapy
* Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.

Primary outcomes:
measure: To determine the safety profile and overall response rate (ORR) of IPI 504 in patients with advanced dedifferentiated liposarcoma.
timeFrame: Every 6 weeks
Secondary outcomes:
measure: To determine the clinical benefit rate and duration of overall response
timeFrame: Every 6 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
References:
Clinical trial NCT05760417: Awareness of Osteoporosis in Patients With Hyperthyroidism
Official title: Awareness of Osteoporosis in Patients With Hyperthyroidism
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hyperthyroidism
Osteoporosis
Osteoporosis Risk
Lead sponsor: Uskudar State Hospital
Sponsor class: OTHER_GOV
First posted: 2023-03-08
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 18 to 90 years with a diagnosis of hyperthyroidism who gave consent to participate in the study.

Brief summary: Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. Multiple sclerosis patients are at increased risk for developing osteoporosis. Identifying whether multiple sclerosis patients have information and awareness about this disease is crucial. This study is aimed to investigate awareness and knowledge of osteoporosis in patients with hyperthyroidism.

Detailed description: Osteoporosis is a common disease of bone loss. The reduced bone strength predisposes an increased risk for fractures in older individuals. It can affect people from different ethnicity. Many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight calcium, vitamin D, immobility, and chronic inflammation. Patients with hyperthyroidism are at high risk of developing osteoporosis due to chronic inflammation and their medications. Patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. This study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with multiple sclerosis.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of hyperthyroidism
* Must be between the ages of 18 and 99
* Must give consent to participate in the study

Exclusion Criteria:

• Not giving consent

Primary outcomes:
measure: Revised Osteoporosis Knowledge Test
timeFrame: 1 day
Secondary outcomes:
measure: Osteoporosis Self-Efficacy Scale
timeFrame: 1 day
measure: Osteoporosis Health Belief Scale
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: Uskudar State Hospital
name: Mustafa H Temel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04710017: Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding
Official title: Tranexamic Acid Versus Depot-Medroxyprogesterone Acetate in the Treatment of Perimenopausal Irregular Uterine Bleeding: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uterine Bleeding
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-01-14
Enrollment: 110
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Abnormal uterine bleeding is a symptom and not a disease. It is one of the most frequently encountered complaints in gynecologic practice. It accounts for more than 70% of all gynecological consultations in the peri- and post-menopausal age group.

Abnormal uterine bleeding may be acute or chronic and is defined as bleeding from the uterine corpus that is abnormal in regularity, volume, frequency, or duration and occurs in the absence of pregnancy.

Chronic heavy or prolonged uterine bleeding can result in anemia, interfere with daily activities. Iron deficiency anemia develops in 21 to 67 percent of cases and raises concerns about uterine cancer.

According to the International Federation of Obstetrics and Gynecology, the classification of abnormal uterine bleeding is based on PALM-COEIN which is an acronym for various etiologies namely polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic and not otherwise classified (PALM-COEIN).


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed, clinically as peri-menopausal abnormal uterine bleeding with normal pelvic examination.
* Patient's age ranging from 40- 55y.

Exclusion Criteria:

* Post menopausal women
* Presence of fibroids, adenomyosis, polyp, adnexal mass, endometrial hyperplasia with atypia, and breast malignancy).
* Patients with uncontrolled hypertension.
* Patient of abnormal bleeding profile.
* history of liver impairment and renal insufficiency
* Patients seeking for surgical management.

Primary outcomes:
measure: Number of bleeding days
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Women Health Hospital - Assiut university
Study officials:
References: